Using antimicrobial adjuvant therapy in cancer treatment: a review

Infectious Agents and Cancer

Bolat Sultankulov¹  Assel Mussabekova¹  Aliya Bekmurzayeva¹  Kenneth Alibek² 

[1] “Nazarbayev University Research and Innovation System” private institution, Nazarbayev University, 53 Kabanbay Batyr Avenue, Astana 010000, Kazakhstan;Republican Scientific Center for Emergency Care, 3 Kerey and Zhanibek Khanov Street, Astana 010000, Kazakhstan

关键词: Neutropenia;    Apoptosis;    Virus;    Bacteria;    Chemotherapy;    Antiviral;    Antibiotic;    Cancer;   

Others  :  803324
DOI  :  10.1186/1750-9378-7-33

 received in 2012-04-20, accepted in 2012-11-05,  发布年份 2012

【 摘 要 】

Recent clinical and pre-clinical data demonstrate that adjuvant antimicrobial therapy is beneficial in cancer treatment. There could be several reasons for this effect, which include treating cancer associated bacteria and viruses, prophylaxis of post-chemotherapy infections due to immunosuppression, and antiproliferative effect of certain antimicrobials. Targeting cancer associated viruses and bacteria with antimicrobial agents is currently used for gastric, cervical, hematopoietic, liver and brain cancer. However this treatment is effective only in combination with conventional therapies. Antimicrobials can also have a direct antiproliferative and cytotoxic effect, and can cause apoptosis. Moreover, some antimicrobials are known to be helpful in overcoming side effects of drugs commonly used in cancer treatment. Chemotherapy related bacteremia and neutropenia can be overcome by the appropriately timed use of antimicrobials. This review summarizes the data on the effects of antivirals and antibiotics on cancer treatment and describes their mechanisms.

【 授权许可】

   
2012 Alibek et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Comprehensive cancer information - national cancer institute. 2012. http://www.cancer.gov/ webcite
• [2]Moore PS, Chang Y: Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010, 10(12):878.
• [3]Saha A, Kaul R, Murakami M, Robertson ES: Tumor viruses and cancer biology modulating signaling pathways for therapeutic intervention. Cancer Biol Ther 2010, 10(10):1-18.
• [4]Lax AJ, Thomas W: How bacteria could cause cancer: One step at a time. Trends Microbiol 2002., 10(6) http://tim.trends.com webcite
• [5]Kwon H, Lok AS: Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther 2011, 16(6):787-795.
• [6]Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK: Virological suppression does not prevent the development of hepatocellular carcinoma in hbeag-negative chronic hepatitis b patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide hepnet. Greece cohort study. Gut 2011.
• [7]Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, Khan Z, Sveinbjornsson B, Fuskevag OM, Segerstrom L, Nordenskjold M: Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Investig 2011, 121(10):4043-4055.
• [8]Soderlund J, Erhardt S, Kast RE: Acyclovir inhibition of ido to decrease tregs as a glioblastoma treatment adjunct. J Neuroinflammation 2010., 7
• [9]Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M: Generation of polyclonal cmv-specific t cells for the adoptive immunotherapy of glioblastoma. J Immunother 2012, 35(2):159-168.
• [10]Krown SE, Dittmer DP, Cesarman E: Pilot study of oral valganciclovir therapy in patients with classic kaposi sarcoma. J Infect Dis 2011, 203(8):1082.
• [11]Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S: Update on kaposi’s sarcoma and other hhv8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002, 2(5):281-292.
• [12]Robles R, Lugo D, Gee L, Jacobson MA: Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed kaposi's sarcoma in patients with aids. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(1):34-38.
• [13]Corey Casper WGN, Meei-Li H, Lawrence C, Anna W: Remission of hhv-8 and hiv-associated multicentric castleman disease with ganciclovir treatment. Blood 2004, 103:1632-1634.
• [14]Iarc monographs- classifications. 2012. http://monographs.iarc.fr/ENG/Classification/ webcite
• [15]Yoshizaki T, Wakisaka N, Kondo S, Murono S, Shimizu Y, Nakashima M, Tsuji A, Furukawa M: Treatment of locally recurrent epstein-barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol 2008, 80(5):879-882.
• [16]Abdulkarim B, Bourhis J: Antiviral approaches for cancers related to epstein-barr virus and human papillomavirus. Lancet Oncol 2001, 2(10):622-630.
• [17]Lee R, Cai J-P, Deyev V, Gill P, Cabral L, Wood C, Agarwal R, Xia W, Boise L, Podack E, Harrington W: Azidothymidine and interferon-a induce apoptosis in herpesvirus associated lymphomas. Cancer Res 1999, 59:5514-5520.
• [18]Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzynveil A, Rio B, Macintyre E, Dreyfus F, Bazarbachi A: Brief report - treatment of adult t-cell leukemia-lymphoma with zidovudine and interferon-alfa. N Engl J Med 1995., 332(26)
• [19]Bazarbachi A, Hermine O: Treatment of adult t cell leukemia/lymphoma: Current strategy and future perspectives. AIDS Res Hum Retroviruses 2001, 17:79-92.
• [20]Hanel M, Fiedler F, Thorns C: Anti-cd20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an ebv-associated lymphoma with cns involvement. Onkologie 2001., 24(5)
• [21]Ayyub M, El-Moursy SA, Al-Abbas F: Outcome of combination antiviral therapy in chronic hepatitis c virus infection during therapy of acute lymphoblastic leukemia. Saudi J Gastroenterol 2011, 17(4):283-286.
• [22]Tamim HM, Musallam KM, Al Kadri HM, Boivin JF, Collet JP: Antibiotic use and risk of gynecological cancer. Eur J Obstet Gynecol Reprod Biol 2011, 159(2):388-393.
• [23]Capelle LG, de Vries AC, Looman CWN, Casparie MK, Boot H, Meijer GA, Kuipers EJ: Gastric malt lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008, 44(16):2470-2476.
• [24]Kim SS, Ruiz VE, Carroll JD, Moss SF: Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett 2011, 305(2):228-238.
• [25]Srikanta BM, Nayaka MAH, Dharmesh SM: Inhibition of helicobacter pylori growth and its cytotoxicity by 2-hydroxy 4-methoxy benzaldehyde of decalepis hamiltonii (wight & arn); a new functional attribute. Biochimie 2011, 93(4):678-688. Epub 2010
• [26]Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli A, Bonanno G, Linea C, Giustini M: Management and long-term follow-up of early stage h. Pylori-associated gastric malt-lymphoma in clinical practice: An italian, multicentre study. Dig Liver Dis 2009, 41(7):467-473. Epub 2008 Oct 21
• [27]Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy D-C, Miller WH Jr, Borden KLB: Molecular targeting of the oncogene eif4e in acute myeloid leukemia (aml): A proof-of-principle clinical trial with ribavirin. Blood 2009., 114(2)
• [28]Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB: Ribavirin suppresses eif4e-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mrna cap. Proc Natl Acad Sci U S A 2004, 101(52):18105-18110.
• [29]Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KLB: Ribavirin treatment effects on breast cancers overexpressing eif4e, biomarker with prognostic specificity for luminal b-type breast cancer. Clin Cancer Res 2011, 17(9):2874-2884. Epub 2011
• [30]Fumo G, Akin C, Metcalfe DD, Neckers L: 17-allylamino-17-demethoxygeldanamycin (17-aag) is effective in down-regulating mutated, constitutively activated kit protein in human mast cells. Blood 2004, 103(3):1078-1084.
• [31]Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ: Targeting hsp90 for cancer therapy. Br J Cancer 2009, 100(10):1523-1529.
• [32]Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J: Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 2009, 100(2):334-343.
• [33]Ding WQ, Liu BL, Vaught JL, Yamauchi H, Lind SE: Anticancer activity of the antibiotic clioquinol. Cancer Res 2005, 65(8):3389-3395.
• [34]Otova B, Hrdy J, Votruba I, Holy A: In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates pmedap and pmeg. Anticancer Res 2009, 29:1295-1302.
• [35]Borden KLB, Culjkovic-Kraljacic B: Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and beyond? Leuk Lymphoma 2010, 51(10):1805-1815.
• [36]Curiel TJ: Tregs and rethinking cancer immunotherapy. J Clin Investig 2007, 117:1167-1174.
• [37]Mondello C, Scovassi AI: Telomeres, telomerase, and apoptosis. Biochemistry and Cell Biology-Biochimie Et Biologie Cellulaire 2004, 82(4):498-507.
• [38]Zhou F-X, Liao Z-K, Dai J, Xiong J, Xie C-H, Luo Z-G, Liu S-Q, Zhou Y-F: Radiosensitization effect of zidovudine on human malignant glioma cells. Biochem Biophys Res Commun 2007, 354(2):354-356. Epub 2007
• [39]Mattson DM, Ahmad IM, Dayal D, Parsons AD, Aykin-Burns N, Li L, Orcutt KP, Spitz DR, Dornfeld KJ, Simons AL: Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. Free Radic Biol Med 2009., 46(2) 10.1016/j.freeradbiomed.2008.10.023
• [40]Wu JJ, Pang KR, Huang DB, Tyring SK: Advances in antiviral therapy. Dermatol Clin 2005, 23(2):313-322.
• [41]Rho YS, Kim WJ, Yoo DJ, Kang RS, Chung SR: Synthesis and antitumor activity of new anthracycline analogues. Bulletin of the Korean Chemical Society 2001, 22(9):963.
• [42]Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229.
• [43]Bhat UG, Halasi M, Gartel AL: Thiazole antibiotics target foxm1 and induce apoptosis in human cancer cells. PLoS One 2009, 4(5):e5592.
• [44]Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimov AV, Tonetti DA, Gartel AL: Thiazole antibiotics against breast cancer. Cell Cycle 2010, 9(6):1214-1217. Epub 2010
• [45]Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I: Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in thp-1 and jurkat cells. Br J Cancer 2006, 95(8):1038-1046.
• [46]Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D: Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002, 86(3):443-448.
• [47]Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP, Sarkar FH: Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 2003, 22(4):787-794.
• [48]Klastersky J: Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004, 39:S32-S37.
• [49]Lin L, Ibrahim AS, Baquir B, Fu Y, Applebaum D, Schwartz J, Wang A, Avanesian V, Spellberg B: Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J Infect Dis 2010, 201(11):1708-1717.
• [50]Walid K, Rami H, Salman N: Infections in hematological malignancies. Dis Mon 2012, 58(4):239-249.
• [51]Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M: A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four eortc studies. Br J Haematol 1997, 99(3):580-588.
• [52]Schimpff S, Satterlee W, Young VM, Serpick A: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971, 284(19):1061-1065.
• [53]Zinner SH: Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999, 29(3):490-494.
• [54]Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the united states. Clin Infect Dis 2003, 36(9):1103.
• [55]Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G: Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant escherichia coli among patients with haematological malignancies: Results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008, 61(3):721-728.
• [56]Oliveira AL, de Souza M, Carvalho-Dias VMH, Ruiz MA, Silla L, Tanaka PY, Simoes BP, Trabasso P, Seber A, Lotfi CJ, Zanichelli MA: Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007, 39(12):775-781.
• [57]Ramphal R: Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004, 39:S25-S31.
• [58]Johnson MP, Ramphal R: Beta-lactam-resistant enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990, 162(4):981-983.
• [59]Johnson PRE, Yin JAL, Tooth JA: A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992, 30(2):203-214.
• [60]Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, Breathnach OS, Smyth E, Humphreys H: Emergence of MRSA in positive blood cultures from patients with febrile neutropenia - a cause for concern. Support Care Cancer 2008, 16(9):1085-1088.
• [61]Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G: Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007, 13(5):615-621.
• [62]Kouranos V, Dimopoulos G, Vassias A, Syrigos KN: Chemotherapy-induced neutropenia in lung cancer patients: The role of antibiotic prophylaxis. Cancer Lett 2011, 313((1):9-14.
• [63]Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology 2004, 63(3):457-460.
• [64]Kamat AM, DeHaven JI, Lamm DL: Quinolone antibiotics: A potential adjunct to intravesical chemotherapy for bladder cancer. Urology 1999, 54(1):56-61.
• [65]Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA: Primary antifungal prophylaxis in leukaemia patients. EJC Suppl 2007, 5(2):43-48.
• [66]Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flueckiger U, Frere P, Gachot B, Heinz WJ, Lass-Floerl C, Ribaud P, Thiebaut A: European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ecil 3-2009 update. Bone Marrow Transplant 2011, 46(5):709-718.
• [67]Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, Mendizabal AM, Leather H, Confer DL, Baden LR, Maziatz RT: Results of a randomized, double-blind trial of fluconazole (flu) vs. Voriconazole (vori) for the prevention of invasive fungal infections (ifi) in 600 allogeneic blood and marrow transplant (bmt) patients. Blood 2007., 110(11)
• [68]Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G, IMPROVIT Study Group: Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011, 155(3):318-327.
• [69]Vehreschild JJ, Boehme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G: A double-blind trial on prophylactic voriconazole (vrc) or placebo during induction chemotherapy for acute myelogenous leukaemia (aml). J Infect 2007., 55(5)
• [70]Ullmann A, Lipton J, Vesole DH, Chandrasekar P, Amelia L, Tarantolo S, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease — nejm. N Engl J Med 2007, 356:335-347.
• [71]Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS: Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981, 305(2):63-67.
• [72]Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ, Lietman PS: Acyclovir prophylaxis against herpes-simplex virus-infection in patients with leukemia - a randomized, double-blind, placebo-controlled study. Ann Intern Med 1983, 99(6):773-776.
• [73]Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA: Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 2006, 107(5):1800-1805.
• [74]Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad A: Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and streptococcus pneumoniae. Medical Oncology 2002, 19(2):71-78.
• [75]Kunisaki KM, Janoff EN: Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(8):493-504.
• [76]Ortbals DW, Liebhaber H, Presant CA, Vanamburg AL, Lee JY: Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977, 87(5):552-557.
• [77]Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH: Immunogenicity of vaccination against influenza, streptococcus pneumoniae and haemophilus influenzae type b in patients with multiple myeloma. Br J Cancer 2000, 82(7):1261-1265.
• [78]Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L, Boeckh M: Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: A retrospective case-control study. Clin Infect Dis 2007., 45(2)
• [79]Martino R, Ramila E, Rabella R, Munoz JM, Peyret M, Portos JM, Laborda R, Sierra J: Respiratory virus infections in adults with hematologic malignancies: A prospective study. Clin Infect Dis 2003, 36(1):1-8.
• [80]Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, Hackman RC, Cent A, Boeckh M: Respiratory virus infection among hematopoietic cell transplant recipients: Evidence for asymptomatic parainfluenza virus infection. Blood 2007, 110(5):1681-1688.
• [81]Nichols WG, Corey L, Gooley T, Davis C, Boeckh M: Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001., 98(3)
• [82]Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA: Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29(4):321-327.
• [83]de Fontbrune FS, Robin M, Porcher R, Scieux C, de latour RP, Ferry C, Rocha V, Boudjedir K, Devergie A, Bergeron A, Gluckman E: Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007, 45(8):1019-1024.
• [84]Symeonidis N, Jakubowski A, Pierre-Louis S, Jaffe D, Pamer E, Sepkowitz K, O'Reilly RJ, Papanicolaou GA: Invasive adenoviral infections in t-cell-depleted allogeneic hematopoietic stem cell transplantation: High mortality in the era of cidofovir. Transpl Infect Dis 2007, 9(2):108-113.